Jasper Therapeutics earnings release, August 14, 2026

Jasper Therapeutics, Inc. (JSPR) · Form 8-K, Item 2.02 · Filed · SEC filing

Jasper Therapeutics Reports Second Quarter 2026

Financial Results and Provides Corporate Update

Acquisition of Kira Pharmaceuticals closed in

July creating a combined company with a robust portfolio of clinical stage assets focused on immunologically-driven disorders

Completed a concurrent PIPE financing raising

$132 million in gross proceeds

REDWOOD CITY, Calif., August 14, 2026 (GLOBE

NEWSWIRE) – Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today reported results for the fiscal quarter ended June 30, 2026, and provided a corporate update.

“

We are excited to unite Jasper Therapeutics and Kira Pharmaceuticals to advance our shared mission of developing a differentiated portfolio of innovative therapies for patients with significant immune-mediated diseases. Supported by our recent $132 million financing led by leading life sciences investors, we believe that we have sufficient capital to fund planned operations through the second half of 2028. We plan to advance development of our lead asset KP-104, a novel dual inhibitor of the complement cascade, in multiple indications, progress briquilimab towards a potential BLA, and to commence first in human studies for KP-701,” said Jeet Mahal, President and Chief Executive

Officer of Jasper. “The combined company now has access to significant resources in the United States and China, which we believe will allow us to rapidly advance our portfolio across multiple diseases of unmet need.”

Corporate Updates for Second Quarter 2026 and Recent Weeks

Second Quarter Fiscal 2026 Financial Results

About Jasper

The combined company is a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases. The combined company is advancing a pipeline of medicines including KP-104, briquilimab, and KP-701. KP-104 is a potential best-in-class dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other high unmet need nephrology disorders. Briquilimab is an anti-KIT antibody which has demonstrated positive clinical results both as a conditioning agent for stem cell transplant and mast cell mediated diseases such as chronic urticarias and allergic asthma. KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders currently advancing to the clinic.

Financial statements

Income Statement

Three Months Ended June 30, 2026 — (unaudited) (in thousands)

Three Months Ended June 30, 2026 – 2026Three Months Ended June 30, 2026 – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Operating expensesResearch and development(1)5,13521,19610,94937,353
Operating expensesGeneral and administrative(1)4,0725,8809,21011,525
Operating expensesTotal operating expenses9,20727,07620,15948,878
Operating expensesLoss from operations-9,207-27,076-20,159-48,878
Operating expensesInterest income824372461,061
Operating expensesChange in fair value of warrant liability3,98013,620
Operating expensesOther income (expense), net2,385-842,359-147
Operating expensesTotal other income, net6,44735316,225914
Operating expensesNet loss and comprehensive loss-2,760-26,723-3,934-47,964
Operating expensesNet loss per share attributable to common stockholders, basic and diluted-0.1-1.74-0.14-3.16
Operating expensesWeighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted28,696,93715,333,96228,684,44715,178,904

Balance Sheet

June 30, 2026 — (unaudited) (in thousands)

June 30, 2026December 31, 2025
Assets Current assets:Cash and cash equivalents7,31428,692
Assets Current assets:Restricted cash, current417
Assets Current assets:Prepaid expenses and other current assets3,8405,953
Assets Current assets:Total current assets11,57134,645
Assets Current assets:Property and equipment, net60102
Assets Current assets:Operating lease right-of-use assets128502
Assets Current assets:Restricted cash, non-current417
Assets Current assets:Other non-current assets43113
Assets Current assets:Total assets11,80235,779
Current liabilities:Accounts payable2,7786,220
Current liabilities:Current portion of operating lease liabilities2701,235
Current liabilities:Accrued expenses and other current liabilities4,7975,745
Current liabilities:Total current liabilities7,84513,200
Current liabilities:Warrant liability2,54416,164
Current liabilities:Other non-current liabilities2,264
Current liabilities:Total liabilities10,38931,628
Preferred stockCommon stock33
Preferred stockAdditional paid-in capital322,014320,818
Preferred stockAccumulated deficit-320,604-316,670
Preferred stockTotal stockholders’ equity1,4134,151
Preferred stockTotal liabilities and stockholders’ equity11,80235,779
Full release

Forward-Looking Statements

Certain statements contained in this press release are or may be considered

“forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements can be identified by the fact that they do not relate strictly to historic or current facts. They use words such as “estimate,” “expect,”

“intend,” “believe,” “plan,” “anticipate,” “potential,” “projected” and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or condition.

Jasper cautions that these statements are based upon the current beliefs and expectations of Jasper’s management and are subject to significant risks, uncertainties and assumptions, including, without limitation, risks related to the market price of Jasper’s common stock relative to the value suggested by the exchange ratio in connection with the merger; unexpected costs, charges or expenses resulting from the merger; potential adverse reactions or changes to business relationships resulting from the announcement or completion of the merger; the uncertainties associated with the Combined Company’s product candidates, as well as risks associated with the clinical development and regulatory approval of product candidates, including potential delays in the commencement, enrollment and completion of clinical trials; risks related to the inability of the Combined Company to obtain sufficient additional capital to continue to advance product candidates and its preclinical programs; uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; risks related to the failure to realize any value from product candidates and preclinical programs being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; risks associated with the possible failure to realize certain anticipated benefits of the merger, including with respect to future financial and operating results; risks related to the integration of Kira and realization of anticipated benefits from the combination; the possibility that holders of CVRs may never receive any proceeds; risks related to the possibility that Jasper’s shareholders may not approve the conversion of the Preferred Stock and the consequences if such approval is not obtained, and such additional risks and uncertainties contained in the “Risk Factors” section of Jasper’s Annual Reports on Form 10-K for the year ended

December 31, 2025, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K that Jasper has subsequently filed or may subsequently file with the SEC. Statements regarding future actions, future performance and/or future results including, without limitation, those relating to the timing for completion, and results of, scheduled or additional clinical trials and the FDA’s or other regulatory review and/or approval and commercial launch and sales results (if any) of the Combined Company’s formulations and product candidates and regulatory filings related to the same, financial projections and targets, including, without limitation, cash runway, operating plans,... (truncated)ness strategy, plans and objectives for future operations, statements regarding the Combined Company and its operations and prospects, may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Accordingly, you should not rely upon forward-looking statements as predictions of future events. There is no obligation to update publicly or revise any forward-looking statements for any reason after the date of this press release or to conform these statements to actual results or to changes in the Combined

Company’s expectations, whether as a result of new information, future events, inaccuracies that become apparent after the date hereof or otherwise, except as may be required under applicable securities laws.

Contacts:

Alex Gray (investors)

Jasper Therapeutics

650-549-1454 agray@jaspertx.com

Argot Partners (investors and media) kira@argotpartners.com²

JASPER THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS

OF OPERATIONS AND COMPREHENSIVE LOSS

(in thousands, except share and per share data)

(unaudited)³

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Jasper Therapeutics earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.